Large-scale randomized trials in early-stage prostate cancer are rare. Data from the recent ProtecT trial enables a cautious endorsement of active monitoring for early-stage, screen-detected prostate cancer: cancer-specific survival was high regardless of treatment approach (monitoring, surgery or radiation). How these findings apply to contemporary prostate cancer care requires careful evaluation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).
Donovan, J. L. et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl. J. Med. 375, 1425–1437 (2016).
Cooperberg, M. R., Lubeck, D. P., Meng, M. V., Mehta, S. S. & Carroll, P. R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J. Clin. Oncol. 22, 2141–2149 (2004).
Gupta, S. K. Intention-to-treat concept: a review. Perspect. Clin. Res. 2, 109–112 (2011).
Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203–213 (2012).
Bill-Axelson, A. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352, 1977–1984 (2005).
Sartor, O. Implications of the prostate intervention versus observation trial (PIVOT). Asian J. Androl. 14, 803–804 (2012).
Popiolek, M. et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur. Urol. 63, 428–435 (2013).
Abramowitz, M. C. et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112, 55–60 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Canes, D. Determining optimal therapy of early-stage disease remains complicated. Nat Rev Urol 13, 703–704 (2016). https://doi.org/10.1038/nrurol.2016.228
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.228
